Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Impact of innate immune memory on inflammation-driven modulation of hematopoietic stem and progenitor cell populations in TET2 loss

Award Number: F31AI198075
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 06/01/2026
PERIOD OF PERFORMANCE END DATE: 05/31/2029

Group Awards By:

View Award Description

Impact of innate immune memory on inflammation-driven modulation of hematopoietic stem and progenitor cell populations in TET2 loss - PROJECT SUMMARY Myelodysplastic syndromes (MDS) are clonal, age-related bone marrow failure disorders that affect aged individuals and are met with limited treatment options, despite high rates of mortality. Mutations in ten-eleven translocation protein 2 (TET2) drive disease in MDS and associate with poor prognosis. However, some individuals with no hematopoietic disorder harbor these mutations and have low probability of progression to disease. It is unknown why some patients with TET2 loss have disease while others will not. Innate immune inflammation elicited by bacterial products drives clonal expansion and disease progression in TET2-deficient mouse models. Yet it is not understood how innate immune inflammation interacts with TET2 loss during physiological challenges throughout an individual’s lifetime, hindering development of therapies. Receptor interacting serine/threonine kinase 1 (RIPK1) plays a central role in inflammatory signaling pathways such as TLR4 signaling, and inactivation of its kinase activity alleviates some of the inflammatory repercussions of TET2 loss, revealing a potential therapeutic target. TET2 loss also impairs effective innate immune cell function and augments inflammation following bacterial infection. In WT mice, prior MPLA exposure (a toll like receptor 4 (TLR4) agonist known to initiate innate memory) improves innate immune function and dampens inflammation during subsequent bacterial infection. The objective of this proposal is to apply the powerful model of innate immune memory to TET2 deficiency and define how infection and incomplete inflammatory resolution promote disease progression. Due to the inflammatory nature of TET2 loss, I hypothesize that inflammation initiated by MPLA with infection persists, promoting disease progression. Additionally, I expect RIPK1 augments inflammation in TET2 loss, playing an essential role in disease progression. To explore these hypotheses, I will apply MPLA-induced innate immune memory to murine models of TET2 deficiency and RIPK1 inactivation, which is unique in its ability to augment pathogen clearance while simultaneously dampening inflammation. Aim 1 will utilize a slowly progressive S. aureus infection model to define innate immune cell function deficits, incomplete inflammatory resolution, and hematopoietic dysregulation in TET2 loss and the function of RIPK1 in moderating these effects. Aim 2 will then elucidate how inflammation and disease progression are altered in TET2 loss by examining differentiation and inflammatory signaling in vitro under MPLA stimulation, following which I will stimulate mice in vivo with different TLR agonists prior to infection to determine the mechanism of hematopoietic dysregulation. These Aims will collectively define how infection-induced inflammation promotes disease progression in TET2 loss, thus promoting our understanding of the biology of clonal expansion in hematologic disease in a physiologically-relevant setting. The results of these studies will have broad translational applicability to advancing treatment options for patients affected with MDS to specifically target inflammatory pathways, which minimize disease progression and improve patient outcomes.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $43,714 )
2026	2026	VANDERBILT UNIVERSITY	110 21ST AVE S	NASHVILLE	TN	37203	DAVIDSON	USA	Allergy and Infectious Diseases Research	000	1	5/27/2026	NEW	$43,714
2026	2026	VANDERBILT UNIVERSITY	110 21ST AVE S	NASHVILLE	TN	37203	DAVIDSON	USA	Allergy and Infectious Diseases Research	001	1	5/27/2026	NEW	$0
														Subtotal = $43,714

Grand Total All Awards = $43,714

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Impact of innate immune memory on inflammation-driven modulation of hematopoietic stem and progenitor cell populations in TET2 loss

Award Number: F31AI198075

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 06/01/2026

PERIOD OF PERFORMANCE END DATE: 05/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer